ZA992447B - Quinoxalinones as serine protease inhibitors. - Google Patents

Quinoxalinones as serine protease inhibitors.

Info

Publication number
ZA992447B
ZA992447B ZA9902447A ZA992447A ZA992447B ZA 992447 B ZA992447 B ZA 992447B ZA 9902447 A ZA9902447 A ZA 9902447A ZA 992447 A ZA992447 A ZA 992447A ZA 992447 B ZA992447 B ZA 992447B
Authority
ZA
South Africa
Prior art keywords
quinoxalinones
protease inhibitors
serine protease
serine
inhibitors
Prior art date
Application number
ZA9902447A
Other languages
English (en)
Inventor
Danette Andrea Dudley
Jeremy John Edmunds
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA992447B publication Critical patent/ZA992447B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9902447A 1998-03-31 1999-03-30 Quinoxalinones as serine protease inhibitors. ZA992447B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8004298P 1998-03-31 1998-03-31

Publications (1)

Publication Number Publication Date
ZA992447B true ZA992447B (en) 2000-10-10

Family

ID=22154891

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9902447A ZA992447B (en) 1998-03-31 1999-03-30 Quinoxalinones as serine protease inhibitors.

Country Status (14)

Country Link
US (2) US6410536B1 (xx)
EP (1) EP1068190A1 (xx)
JP (1) JP2002509923A (xx)
KR (1) KR20010042298A (xx)
AU (1) AU1917999A (xx)
BR (1) BR9815785A (xx)
CA (1) CA2319554C (xx)
HU (1) HUP0101470A3 (xx)
IL (1) IL137655A0 (xx)
IS (1) IS5589A (xx)
NO (1) NO20004697D0 (xx)
PL (1) PL343321A1 (xx)
WO (1) WO1999050254A1 (xx)
ZA (1) ZA992447B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
CA2320730A1 (en) * 1998-12-23 2000-07-06 Renhua Li Thrombin or factor xa inhibitors
EP1150979A1 (en) * 1999-02-09 2001-11-07 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
SE9902202D0 (sv) * 1999-06-10 1999-06-10 Astra Ab Production of aggregates
EP1255741A2 (en) * 2000-02-01 2002-11-13 Cor Therapeutics, Inc. 2- 1H]-QUINOLONE AND 2- 1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
HUE025683T2 (hu) 2002-12-03 2016-04-28 Pharmacyclics Llc VIIA faktor inhibitor 2-(2-hidroxi-bifenil-3-il)-1H-benzoimidazol-5-karboxamidin-származékok
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
WO2004091486A2 (en) * 2003-04-15 2004-10-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2007505160A (ja) * 2003-05-20 2007-03-08 ジェネンテック・インコーポレーテッド 第VIIa因子のアシルスルファミド阻害剤
CA2525713A1 (en) * 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor viia
US20080200424A1 (en) * 2004-05-05 2008-08-21 Christine Grimm Preparation for Treating Cancer
DE102004023332A1 (de) * 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2006016278A1 (en) * 2004-08-09 2006-02-16 Warner-Lambert Company Llc Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
WO2006016450A1 (ja) 2004-08-11 2006-02-16 Kowa Company, Ltd. 脳梗塞の予防・治療方法
AP2007003973A0 (en) * 2004-10-12 2007-07-30 Glenmark Pharmaceuticals Sa Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
CA2665476A1 (en) 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
JP2010523653A (ja) 2007-04-09 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルCoAデサチュラーゼのインヒビターとして使用するためのプテリジノン誘導体
JP2010526825A (ja) * 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンゾ−1,4−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
KR20140139125A (ko) 2007-08-31 2014-12-04 퍼듀 퍼머 엘피 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
EP2247580B1 (en) * 2008-03-05 2015-07-08 Merck Patent GmbH Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
MX2010010504A (es) * 2008-03-26 2010-12-15 Daiichi Sankyo Co Ltd Derivado de hidroxi-quinoxalin-carboxamida.
EP2276748A1 (en) * 2008-04-10 2011-01-26 Gilead Sciences, Inc. Bicyclic nitrogen containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
BRPI0911031B8 (pt) 2008-07-21 2021-05-25 Purdue Pharma Lp compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
EP2654751B1 (en) 2010-12-22 2016-11-23 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
JP2015501793A (ja) 2011-11-10 2015-01-19 オーエスアイ・ファーマシューティカルズ,エルエルシー ジヒドロプテリジノン類
AU2012324015A1 (en) 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014102589A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
EP3328839A1 (en) * 2015-07-30 2018-06-06 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
PL3394046T3 (pl) 2015-12-24 2022-06-13 The Regents Of The University Of California Regulatory cftr i sposoby ich zastosowania
PL3394040T3 (pl) 2015-12-24 2022-05-02 The Regents Of The University Of California Regulatory cftr i sposoby ich zastosowania
KR20180101415A (ko) 2015-12-24 2018-09-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 사용 방법
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082735A (en) 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
US4082736A (en) 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
JPS63145272A (ja) 1986-12-09 1988-06-17 Morishita Seiyaku Kk 4,5−ジヒドロ−6−(4−置換フエニル)−3(2h)−ピリダジノン誘導体
JPS63301874A (ja) * 1987-03-27 1988-12-08 Fujisawa Pharmaceut Co Ltd キノキサリン誘導体およびその製造法
JPH0276860A (ja) * 1987-10-05 1990-03-16 Toyo Jozo Co Ltd 6−置換アルコキシ−2−オキソ−1,2−ジヒドロキノキサリン誘導体
JPH01254348A (ja) 1988-04-01 1989-10-11 Matsushita Electric Ind Co Ltd 成形用型
HUT76640A (en) 1995-08-17 1997-10-28 Chinoin Gyogyszer Es Vegyeszet Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use
AU3232597A (en) * 1996-06-18 1998-01-07 Warner-Lambert Company Pyrrolo{1,2-a}pyrazine-1,4-dione serine protease inhibitors
JP2002514162A (ja) * 1996-07-08 2002-05-14 デュポン ファーマシューティカルズ カンパニー Xa因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
GB2324729B (en) 1997-04-30 2002-01-02 Bradford Hospitals Nhs Trust Lung treatment device

Also Published As

Publication number Publication date
WO1999050254A1 (en) 1999-10-07
PL343321A1 (en) 2001-08-13
CA2319554C (en) 2005-06-28
HUP0101470A3 (en) 2002-09-30
NO20004697L (no) 2000-09-20
BR9815785A (pt) 2000-12-05
US6410536B1 (en) 2002-06-25
HUP0101470A2 (hu) 2001-10-28
US6916805B2 (en) 2005-07-12
NO20004697D0 (no) 2000-09-20
EP1068190A1 (en) 2001-01-17
JP2002509923A (ja) 2002-04-02
IL137655A0 (en) 2001-10-31
US20020086866A1 (en) 2002-07-04
IS5589A (is) 2000-08-18
AU1917999A (en) 1999-10-18
CA2319554A1 (en) 1999-10-07
KR20010042298A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
PL349192A1 (en) Protease inhibitors
IL142398A0 (en) Serine protease inhibitor
ZA983629B (en) Serine protease inhibitors
ZA992445B (en) Benzoxazinones/benzothiazinones as serine protease inhibitors.
ZA971733B (en) Serine protease inhibitors.
EP1093367A4 (en) PROTEASE INHIBITORS
ZA971667B (en) Serine protease inhibitors.
EP1067894A4 (en) PROTHEASEINHIBITOREN
EP1079821A4 (en) PROTEASE INHIBITORS
GB9800817D0 (en) Serine protease inhibitors
AU1393900A (en) Morpholino-ethoxybenzofuran protease inhibitors
EP1179052A4 (en) SERINE PROTEASES
EP1232155A4 (en) PROTEASE INHIBITORS
EP1086083A4 (en) PROTEASE INHIBITORS
HK1041690A1 (zh) 蛋白酶抑制劑
EP1231921A4 (en) PROTEASE INHIBITORS
EP1229915A4 (en) PROTEASE INHIBITORS
EP1229912A4 (en) PROTEASE INHIBITORS
EP1229914A4 (en) PROTEASE INHIBITORS
EP1173429A4 (en) PROTEASE INHIBITORS
EP1161237A4 (en) PROTEASE INHIBITORS
EP1229911A4 (en) PROTEASE INHIBITORS
EP1231923A4 (en) PROTEASE INHIBITORS